The White House is intensifying pressure on Republican lawmakers to pass legislation codifying a “most-favored nation” drug pricing policy, even as congressional resistance hardens. Simultaneously, a report from a U.S. senator has renewed scrutiny of GSK’s decision to discontinue two formulations of its widely prescribed asthma inhaler and replace them with an authorized generic sold at a substantially higher price, a maneuver that investigators say created considerable barriers to treatment access for pediatric and adult patients alike.

The two developments, though distinct in origin, converge on a central question confronting American pharmaceutical policy in early 2026: who bears the cost when drug pricing mechanisms fail to protect patients.

The Most-Favored-Nation Push

The administration’s most-favored-nation pricing proposal would require the United States to pay no more for prescription drugs than the lowest price paid by peer nations, a group that typically includes Canada, the United Kingdom, Germany, France, and Japan. The concept has circulated in policy circles for years, but the current White House has moved to position it as a legislative priority within a broader health care package that would affect providers, insurers, federal agencies, and patients.

Congressional Republicans have not received the proposal warmly. Several officials have characterized the effort as government overreach inconsistent with free-market principles, a framing that reflects longstanding ideological tensions over federal intervention in pharmaceutical pricing. Despite this reception, the administration has not moderated its position. The pressure campaign directed at Capitol Hill is, by multiple accounts, continuing to intensify.

The most-favored-nation framework carries a particular complexity that critics and supporters alike acknowledge. Proponents argue that American patients should not subsidize lower drug prices for citizens of other developed nations, and that international reference pricing represents a straightforward corrective. Opponents, including many within the pharmaceutical industry and some economists, contend that prices in peer nations are artificially suppressed through regulatory mechanisms that reduce incentives for research and development investment. They warn that applying those price floors to the American market could depress future drug development pipelines.

Neither claim has been settled through the kind of rigorous prospective analysis that would allow a definitive policy conclusion. What the available evidence does demonstrate is that the United States pays substantially more than peer nations for the same pharmaceutical products across nearly every therapeutic category. A 2024 report from the Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services found that U.S. net prices for brand-name drugs were, on average, nearly three times higher than those in 33 comparable countries. That disparity has persisted across administrations and legislative sessions, and it frames the administration’s current push with a degree of empirical weight that opponents have struggled to fully address.

Whether the proposal can achieve legislative traction is a separate question. The Republican majority in the Senate has shown limited appetite for a measure that their own members have publicly described in unfavorable terms. The administration’s continued pressure suggests a calculation that public opinion, particularly among patients facing high out-of-pocket drug costs, may eventually shift the political calculus on Capitol Hill.

The GSK Flovent Transition and Its Consequences

The second issue receiving renewed attention involves GSK and its handling of the Flovent inhaler product line, a case that illustrates how corporate pricing decisions made within regulatory frameworks can produce outcomes that directly harm patients.

Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder, were among the most widely prescribed inhaled corticosteroids for asthma management in the United States. In May 2022, GSK discontinued both branded formulations and transitioned to selling only an authorized generic version of the product. Authorized generics are chemically and therapeutically identical to their brand-name counterparts. They are manufactured by the same company and contain the same active ingredient, formulation, and delivery mechanism. The distinction is primarily one of labeling and market classification.

Under the Medicaid Drug Rebate Program, pharmaceutical manufacturers are required to pay rebates to state Medicaid programs based on the prices of their brand-name products. Authorized generics, however, are classified differently and are subject to a separate rebate calculation that has historically resulted in lower rebate obligations for manufacturers. By discontinuing the branded Flovent products and substituting an authorized generic at a price point above that of the former brand, GSK restructured its Medicaid financial obligations in a manner that critics, including the office of Senator Maggie Hassan of New Hampshire, argue prioritized corporate financial benefit over patient access.

Senator Hassan’s report, released in 2026, found that the consequences of this maneuver were not confined to the federal budget. The transition set in motion a series of responses from health plans and pharmacy benefit managers (PBMs). Because the authorized generic did not carry the same formulary status as the discontinued Flovent branded products, and because its pricing structure differed from what insurers and PBMs had previously contracted for, many plans restructured their coverage terms. Patients who had previously accessed Flovent with minimal cost-sharing found themselves facing prior authorization requirements, step therapy protocols, or higher out-of-pocket expenses.

For patients managing asthma, particularly children whose treatment regimens depend on consistent access to inhaled corticosteroids, these access barriers carried clinical consequences. Asthma is a chronic inflammatory airway disease affecting an estimated 25 million individuals in the United States, with disproportionate prevalence among pediatric populations and low-income communities. Inhaled corticosteroids represent the foundation of long-term asthma control therapy in clinical guidelines issued by the National Asthma Education and Prevention Program. Interruptions in access to these medications are associated with increased rates of exacerbation, emergency department visits, and hospitalization.

The families who reported substantial financial and treatment problems following the Flovent transition were not navigating an abstract policy failure. They were managing a chronic disease in real time, and the structural changes triggered by GSK’s pricing decision created tangible disruptions in their ability to do so.

GSK has not been alone in employing authorized generic strategies to manage Medicaid rebate exposure. The practice has been documented across multiple manufacturers and therapeutic categories. Policymakers have periodically proposed closing the authorized generic rebate calculation differential, but legislative action has not followed. Senator Hassan’s report adds to a body of documented evidence that the gap between regulatory intent and real-world patient outcomes in this area merits formal legislative attention.

Convergent Pressures on Pharmaceutical Policy

The two stories, read together, reflect a pharmaceutical policy environment under considerable strain. The most-favored-nation debate engages fundamental questions about the relationship between innovation incentives and price regulation. The Flovent case illustrates how existing regulatory structures, designed with one set of goals in mind, can be navigated by manufacturers in ways that produce outcomes inconsistent with those goals.

Both situations also share a common feature: the patients most affected tend to be among those with the least capacity to absorb the financial and logistical consequences of policy failure. Medicaid enrollees, who represent a substantial portion of those affected by the Flovent transition, are by definition low-income. Patients facing the highest out-of-pocket drug costs under the current pricing structure are disproportionately those managing chronic or serious conditions who require ongoing pharmaceutical therapy.

The administration’s most-favored-nation proposal, whatever its legislative prospects, reflects a recognition that the current pricing structure produces outcomes that are difficult to defend on public health grounds. Senator Hassan’s Flovent report reflects a parallel recognition that existing Medicaid rebate regulations contain structural vulnerabilities that manufacturers have demonstrated willingness to exploit.

Neither problem admits of a simple solution. International reference pricing introduces real complexities around market incentives and pharmaceutical investment. Closing authorized generic rebate differentials requires careful attention to how those changes interact with the broader generic drug market, where lower prices are generally the intended outcome. Medical and policy researchers have noted that crude regulatory interventions in pharmaceutical pricing can produce unintended consequences that persist long after the political moment that prompted them has passed.

What the current evidence supports is a period of rigorous policy analysis, informed by study designs capable of capturing both the access effects and the longer-term innovation effects of proposed changes. Observational data already available suggest the cost of inaction is not neutral. It is borne, with measurable regularity, by patients.

Looking Ahead

Congressional deliberations on the White House’s health care package are expected to continue in the coming months, though the timeline for any legislative action remains uncertain given the resistance observed among Republican members whose support would be necessary for passage. Senator Hassan’s report on the Flovent transition has been referred to relevant committee staff, and advocates for asthma patients have called for hearings.

The authorized generic rebate question may find a path forward as part of the broader Medicaid policy discussions already underway on Capitol Hill, where budget negotiations have kept pharmaceutical rebate structures under active consideration. Whether the Flovent case provides sufficient political momentum to address that specific regulatory gap is a question the current session will begin to answer.

For the patients and families who navigated disrupted asthma care following the 2022 Flovent transition, the pace of legislative response has already carried a cost that no future policy correction will fully remediate.